14.05.2018 22:20:00

Hanger Reports Full Year 2017 Results

AUSTIN, Texas, May 14, 2018 /PRNewswire/ -- Hanger, Inc. (OTC PINK: HNGR), the leading provider of orthotic and prosthetic patient care services and solutions, today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2017 with the Securities and Exchange Commission (SEC). The Annual Report on Form 10-K contains information pertaining to the Company's quarterly, year-to-date and annual results for 2017.  

"Hanger remains on schedule to achieve the financial reporting goals we provided in January, specifically a transition to current SEC filer status in 2018," stated Thomas Kiraly, Executive Vice President and Chief Financial Officer of Hanger, Inc. "We are now focused on preparing our interim financial statements for the three months ended March 31, 2018, and our intention is to file our first quarter Form 10-Q as expeditiously as possible."

Subsequent to reporting and filing Hanger's second quarter 2018 results, the Company currently plans to commence the process of relisting on a national securities exchange, which it anticipates will occur in the autumn timeframe. 

Vinit Asar, President and Chief Executive Officer of Hanger, Inc., stated, "Hanger stands at an important inflection point in our corporate journey. In addition to the multi-year investments made to strengthen our infrastructure, we have also dedicated substantial resources and shareholder capital to advance Hanger's leadership in the orthotics and prosthetics (O&P) industry."

Mr. Asar continued, "We are pleased to have achieved a return to same clinic revenue growth in 2017. Our patient care segment exited 2017 with fourth quarter same clinic revenue growth per day of 2.1 percent and full year net revenue growth of 1.4 percent. These results were driven by an annualized return to positive same clinic growth and higher net revenue yield after a year of investment in key revenue cycle management initiatives during 2016 and early 2017. These actions, combined with initiatives to manage costs, led to double digit growth in profitability as well as free cash flow improvements compared to 2016."

Mr. Asar concluded, "While we still have much to accomplish, we plan to prudently invest in our business to maximize our potential, and ensure Hanger successfully achieves the requirements of health care's triple aim: better care, better health and better value. Powering this goal is the hard work and dedication of our 4,600 associates who help bring life-changing improvements to the patients we serve every day." 

Financial Highlights for 2017 Compared to 2016

  • Net revenue in 2017 of $1.041 billion, compared to $1.042 billion for 2016.
                                                       
    • Net revenue declined by $1.3 million, or 0.1 percent. Growth in the Patient Care segment (82 percent of net revenue) was offset by a decline in the Company's Products and Services segment, primarily due to decreased therapeutics solutions revenue.
                                                        
    • The Patient Care segment benefited from improvements in claims documentation processes during 2016, which reduced disallowed revenue by $12.4 million.
                                                        
    • Same clinic revenue growth was 0.8 percent for the year ended December 31, 2017 and 2.1 percent for the three month period ended December 31, 2017. These growth rates exclude the favorable effect of improvements in disallowance trends.
                                                        
  • GAAP loss from continuing operations was $104.7 million in 2017, compared to $107.4 million in 2016. Non-GAAP Adjusted EBITDA was $119.6 million compared to $108.5 million in 2016, an increase of $11.1 million year-over-year.
                                                      
  • GAAP results include charges for the impairment of intangible assets, allowance for deferred tax assets, amortization expense, third party professional fees and severance expense.
                                                                     
    • The charges for the non-cash impairment of intangible assets related to the Products and Services segment and totaled $54.7 million and $86.2 million in 2017 and 2016, respectively.
                                                        
    • Expenses for third party professional fees incurred in connection with financial statement remediation, in excess of historical amounts, totaled $32.3 million and $37.2 million in 2017 and 2016, respectively.
                                                        
  • Growth in earnings prior to charges and expenses for third party fees resulted primarily from increased contribution and margin expansion within the Patient Care segment that was partially offset by decreased earnings from the Products and Services segment and increased bonus expense.
                                                      
  • GAAP diluted loss per share was $2.89 in 2017, compared to $2.96 in 2016. Non-GAAP adjusted diluted income per share was $0.33 in 2017, compared to $0.39 in 2016.
                                                        
    • Non-GAAP income on a per share basis was negatively impacted by a $12.5 million increase in GAAP interest expense in 2017 compared to 2016 (or approximately $0.21 per share).

Complete reconciliations of GAAP to non-GAAP financial measures are provided in the tables located at the end of this press release.

Detailed Results: 2017 and 2016

For 2017, the Company's net revenue of $1.041 billion declined $1.3 million, or 0.1 percent, compared to 2016. The net revenue result was driven by an $11.8 million, or 1.4 percent increase in the Patient Care segment which was offset by a $13.1 million, or 6.5 percent, decrease in the Products & Services segment.

Patient Care Segment

For 2017, the Company's Patient Care net revenue totaled $852.0 million, an increase of $11.8 million compared to 2016. The net revenue growth was primarily the result of lower disallowed revenue and resumed same clinic revenue growth during 2017.

    • In 2016 the Company launched an initiative in the Patient Care segment to improve claims documentation and submission procedures. While these efforts impacted clinic-level productivity and lowered clinical throughput during 2016 and early 2017, the Company benefited from resulting improvements in disallowed sales during 2017. Patient Care disallowed revenue decreased by $12.4 million to $37.0 million, or 4.2 percent of segment Adjusted Gross Revenue, as compared with $49.4 million, or 5.6 percent of segment Adjusted Gross Revenue, in 2016.
                                                        
    • Same clinic revenue per day grew 0.8 percent for the full year 2017 and 2.1 percent during the fourth quarter of 2017, excluding the favorable effect of improvements in disallowed revenue.

Income from operations before interest expenses and income taxes for the Patient Care segment were $122.4 million during 2017, which reflected an increase of $29.7 million over the $92.7 million reported in the prior year. Adjusted EBITDA for the segment was $148.0 million, which reflected a $25.9 million increase over the prior year period.

    • In addition to the favorable effect of earnings flow-through relating to the $12.4 million decrease in disallowed revenue, the Patient Care segment also benefited from a $10.6 million in net non-personnel related expense reductions. These reductions were primarily comprised of savings in lease, material costs, telecommunications and bad debt expenses.
                                                        
    • The Patient Care segment reflected a net personnel expense decrease of $3.2 million year-over-year, which was comprised of a $12.6 million decrease in salaries, benefits, payroll taxes and related employment costs. This was partially offset by increased bonus and commission expenses of $9.4 million. During 2016 and 2017, in connection with ongoing assessments of clinic locations and performance, the Company closed certain underperforming clinics and realigned segment administrative functions. These actions contributed to the decrease in personnel expenses achieved in 2017.
                                                        
    • Income from operations also benefited from a $3.5 million decrease in depreciation and amortization expense, as compared to the prior year.

Products & Services Segment

For 2017, the Company's Products & Services net revenue totaled $188.8 million, a $13.1 million decrease compared to 2016. The revenue decline was due to the net loss of customer contracts for therapeutic solutions, which provides services to the post-acute market, primarily within skilled nursing facilities (SNFs).

    • Hanger recognized approximately $60.1 million in revenues from therapeutic solutions in 2017. The Company currently estimates that it could experience a decline of approximately $8 million from these services in 2018. The Company is currently pursuing strategies to stabilize and maximize
                                                        
    • Revenue from the distribution of O&P componentry to independent providers, which constitutes over 68 percent of total Products and Services segment revenue, increased slightly in 2017 and is anticipated to reflect modest growth in 2018.

Loss from operations before interest expenses and income taxes for the Products and Services segment decreased by $24.1 million to $27.7 million in 2017 from $51.8 million in the prior year. Adjusted EBITDA for the Products and Services segment was $38.5 million in 2017 which reflected a $10.1 million decrease as compared with segment Adjusted EBITDA of $48.6 million in the prior year.

    • The decrease in the segment's loss from operations primarily related to a reduction in non-cash charges for the impairment of goodwill and intangible assets relating to the Product & Services segment. The Company recorded a charge of $54.7 million in 2017 compared to a charge of $86.2 million in 2016.  

Net Loss from Operations; Interest Expense

For 2017, net loss from operations was $19.7 million compared with a net loss from operations of $72.1 million in 2016.

    • In addition to the reduction of non-cash charges for the impairment of goodwill and intangible assets discussed above, the Company also benefited from decreases in its materials costs, personnel costs, other operating costs, professional accounting and legal fees, and depreciation and amortization expenses in 2017.
                                                        
    • Net personnel cost savings of $2.4 million were attained through a decrease in salaries, benefits and other personnel costs associated with reduction in force undertaken in the fourth quarter of 2016, as well as clinic closures, which were partially offset by increased bonus expenses.

Interest expense for 2017 increased to $57.7 million from $45.2 million in 2016. This $12.5 million increase resulted from $10.7 million higher interest expense associated with the Company's debt refinancing in the third quarter of 2016 and $1.8 million related to an increase in interest rates and borrowings.

Liquidity

On December 31, 2017, the Company had liquidity of $87.9 million, comprised of $1.5 million in cash and cash equivalents, and $86.4 million in available borrowing capacity under its revolving credit facility, compared to $102.1 million of liquidity as of December 31, 2016. The $14.2 million decrease in liquidity from 2016 was the result of lower revolver capacity as well as uses of cash to reduce long-term indebtedness and other investing activity. 

Business Update and Preliminary Q1 and 2018 View

The Company has not yet completed the preparation of its financial statements for the quarter ended March 31, 2018. However, it has previously provided certain preliminary estimates of its cash flows and liquidity in a Current Report on Form 8-K filed with the SEC on May 11, 2018.  

The Company preliminarily estimates that consolidated net revenue for the three months ended March 31, 2018 will be approximately $234 million, which is generally consistent with net revenue reported for the first quarter of 2017. The Company's estimate of net revenue includes:

    • Modest Patient Care segment revenue growth, driven primarily by same clinic revenue per day growth of approximately 1.1 percent. 
                                                        
    • Declines in the Products and Services segment, offsetting Patient Care growth, driven by therapeutic solutions.

The Company currently anticipates modest year-over-year growth in Adjusted EBITDA in the first quarter of 2018, driven by favorable expense trends including lower benefit expense compared to the first quarter of 2017. 

For the full year 2018, the Company currently anticipates net revenue and Adjusted EBITDA to be generally consistent with actual 2017 results. In addition, as a result of the Company completing its debt refinancing in the first quarter of 2018, interest expense for the full year is expected to be approximately $40 million, which reflects an approximately $18 million decrease as compared to 2017.

All amounts relating to 2018 for the first quarter and full year are preliminary and subject to material change as the Company completes the preparation and review of its financial statements for the quarter ended March 31, 2018 and otherwise further evaluates its expectations for annual results.

Additional Notes

A reconciliation of GAAP and non-GAAP financial results is included in the tables provided at the back of this press release. The Company has provided certain supplemental key statistics relating its results for the full years 2014–2016. These key statistics are non-GAAP measures used by the Company's management to analyze the Company's business results that are being provided for informational and analytical context.

Conference and Webcast Details

Hanger's management team will host a conference call on Tuesday, May 15, at 8:30 am Eastern Time to discuss the Company's 2017 financial results and business outlook.

To participate, dial 877-407-6184 or 201-389-0877 outside the U.S. and Canada, and use conference code number 13680014. A live webcast and replay of the call will be available at the Investor Relations section of the Company's web site at www.hanger.com/investors, and a replay of the webcast will remain available for 90 days. 

Accompanying supplemental information will be posted to the Investor Relations section of Hanger's web site at www.hanger.com/investors.

About Hanger, Inc. – Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger, Inc. (OTC PINK: HNGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market. Hanger's Patient Care segment is the largest owner and operator of O&P patient care clinics with approximately 800 patient care locations nationwide. Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. With over 150 years of clinical excellence and innovation, Hanger's vision is to lead the orthotic & prosthetic markets by providing superior patient care, outcomes, services and value. For more information on Hanger, visit www.hanger.com.

This press release contains certain "forward-looking statements" relating to the Company. All statements, other than statements of historical fact included herein, are "forward‑looking statements," including statements regarding the timing of filing of, and the outcome of the Company's work in connection with, completing certain financial statements and other financial data. These forward-looking statements are often identified by the use of forward-looking terminology such as "preliminary," "intends," "expects," "plans" or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. These uncertainties include, but are not limited to, the risk that additional information may arise during the course of the Company's ongoing financial statement preparation and closing processes that would require the Company to make additional adjustments or revisions to its estimates or financial statements and other financial data, to identify additional material weaknesses, or to take any other necessary action relating to the Company's accounting practices; the time required to complete the Company's financial statements and other financial data and accounting review; the time required to prepare its periodic reports for filings with the Securities and Exchange Commission; the impact of the Tax Cuts and Jobs Act on the Company's financial statements; any regulatory review of, or litigation relating to, the Company's accounting practices, financial statements and other financial data, periodic reports or other corporate actions; changes in the demand for our O&P products and services; uncertainties relating to the results of operations or recently acquired O&P patient care clinics; the Company's ability to enter into and derive benefits from managed-care contracts; the Company's ability to successfully attract and retain qualified O&P clinicians; federal laws governing the health care industry; uncertainties inherent in investigations and legal proceedings; governmental policies affecting O&P operations;  and other risks and uncertainties generally affecting the health care industry. For additional information and risk factors that could affect the Company, see its Form 10‑K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission. The information contained in this press release is made only as of the date hereof, even if subsequently made available by the Company on its website or otherwise.

Investor Relations Contacts:
Thomas Kiraly, Executive Vice President and Chief Financial Officer, Hanger, Inc.
Seth Frank, Vice President, Treasury and Investor Relations, Hanger, Inc.
512-777-3690, InvestorRelations@hanger.com

Table 1

Hanger, Inc.

Consolidated Balance Sheets

(dollars in thousands, except par value and share amounts)








As of December 31,



2017


2016

ASSETS





Current assets:





Cash and cash equivalents


$         1,508


$         7,157

Net accounts receivable, less allowance for doubtful accounts of $14,065
and $15,521 in 2017 and 2016, respectively


146,346


144,562

Inventories


69,138


68,225

Income taxes receivable


13,079


13,200

Other current assets


20,888


19,137

Total current assets


250,959


252,281






Non-current assets:





Property, plant and equipment, net


93,615


100,467

Goodwill


196,343


249,678

Other intangible assets, net


21,940


32,941

Deferred income taxes


68,126


94,223

Other assets


9,440


25,514

Total assets


$     640,423


$     755,104






LIABILITIES AND SHAREHOLDERS' EQUITY





Current liabilities:





Current portion of long-term debt


$         4,336


$       30,944

Accounts payable


48,269


50,549

Accrued expenses and other current liabilities


65,838


78,950

Accrued interest payable


845


662

Accrued compensation related costs


53,005


36,162

Total current liabilities


172,293


197,267






Long-term liabilities:





Long-term debt, less current portion


445,928


441,706

Other liabilities


50,253


50,717

Total liabilities


668,474


689,690






Commitments and contingent liabilities










Shareholders (Deficit) Equity:










Common stock, $.01 par value; 60,000,000 shares authorized;
36,515,232 shares issued and 36,372,411 shares outstanding in 2017,
and 36,183,894 shares issued and 36,041,073 shares outstanding in 2016


365


362

Additional paid-in capital


333,738


322,191

Accumulated other comprehensive loss


(1,686)


(1,440)

Retained deficit


(359,772)


(255,003)

Treasury stock, at cost 142,821 shares at 2017 and 2016, respectively


(696)


(696)

Total shareholders (deficit) equity


(28,051)


65,414

Total liabilities and shareholders' (deficit) equity


$     640,423


$     755,104






 

Table 2

Hanger, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(dollars in thousands, except share and per share amounts)






For the Years Ended December 31,



2017


2016


2015








Net revenue


$  1,040,769


$  1,042,054


$  1,067,172

Material costs


329,223


332,071


336,283

Personnel costs


361,090


363,537


367,094

Other operating costs


129,831


139,024


140,839

General and administrative expenses


110,078


107,224


111,761

Professional accounting and legal fees


36,239


41,233


28,647

Depreciation and amortization


39,259


44,887


46,343

Impairment of intangible assets


54,735


86,164


385,807

Loss from operations


(19,686)


(72,086)


(349,602)








Interest expense, net


57,688


45,199


29,892

Loss on extinguishment of debt


-


6,031


7,237

Loss from continuing operations before income taxes


(77,374)


(123,316)


(386,731)








Provision (benefit) for income taxes


27,297


(15,910)


(67,614)

Loss from continuing operations


(104,671)


(107,406)


(319,117)

Income (loss) from discontinued operations, net of income taxes


-


935


(7,974)

Net loss


$   (104,671)


$   (106,471)


$   (327,091)








Other comprehensive (loss) income:







Unrealized (loss) gain on DB SERP, net of income tax (benefit) provision
of $(151), $(16) and $81 for 2017, 2016, and 2015, respectively


$          (246)


$            (26)


$            474

Comprehensive loss


$   (104,917)


$   (106,497)


$   (326,617)








Basic and Diluted Per Common Share Data:







Loss from continuing operations


$         (2.89)


$         (2.99)


$         (8.96)

Income (loss) from discontinued operations, net of income taxes


-


0.03


(0.22)

Basic and diluted loss per common share


$         (2.89)


$         (2.96)


$         (9.18)








Shares used to compute basic and diluted per common share amounts


36,270,920


35,933,222


35,635,448















 

Table 3

Hanger, Inc.

Consolidated Statements of Cash Flows

(dollars in thousands)










For the Years Ended December 31,



2017


2016


2015

Cash flows from operating activities:







Net loss


$   (104,671)


$   (106,471)


$   (327,091)

Income (loss) from discontinued operations, net of income taxes


-


935


(7,974)

Loss from continuing operations


(104,671)


(107,406)


(319,117)








Adjustments to reconcile net loss to net cash provided by operating activities:







Depreciation and amortization


39,259


44,887


46,343

Provision for doubtful accounts


9,422


13,727


12,854

Impairment of long-lived and intangible assets


54,735


86,164


385,807

Stock-based compensation expense


12,930


9,763


11,134

Provision (benefit) for deferred income taxes


26,248


4,031


(48,926)

Amortization of debt issuance costs


8,876


4,921


3,371

Loss on extinguishment of debt


-


6,031


7,237

Gain on sale and disposal of fixed assets


(2,059)


(5,055)


(2,384)








Changes in operating assets and liabilities, net of effects of acquired companies:







Net accounts receivable


(12,585)


17,612


(13,625)

Inventories


(913)


253


2,520

Other current assets


661


849


3,913

Income taxes


121


18,725


(40,152)

Accounts payable


(3,562)


(3,133)


8,084

Accrued expenses and accrued interest payable


(12,929)


(3,045)


(6,264)

Accrued compensation related costs


16,843


(12,006)


6,877

Other liabilities


(2,271)


(5,797)


6,940

Net cash provided by operating activities - continuing operations


30,105


70,521


64,612

Net cash used in operating activities - discontinued operations


-


(1,425)


(5,098)

Net cash provided by operating activities


30,105


69,096


59,514








Cash flows from investing activities:







Purchase of property, plant and equipment


(16,355)


(21,148)


(27,620)

Purchase of equipment leased to third parties under operating leases


(6,000)


(2,476)


(4,632)

Acquisitions, net of cash acquired


-


-


(10,215)

Restricted cash


(1,016)


1,615


(54)

Proceeds from company-owned life insurance investment


17,135


-


-

Purchase of company-owned life insurance investment


(555)


(2,543)


(2,544)

Proceeds from sale of property, plant and equipment


4,909


5,960


4,954

Other investing activities, net


-


(10)


(50)

Net cash used in investing activities - continuing operations


(1,882)


(18,602)


(40,161)

Net cash provided by investing activities - discontinued operations


-


1,425


4,987

Net cash used in investing activities


(1,882)


(17,177)


(35,174)








Cash flows from financing activities:







Borrowings under term loan


420


274,400


-

Repayment of term loan


(28,545)


(19,688)


(14,063)

Borrowings under revolving credit agreement


156,965


23,000


155,000

Repayments under revolving credit agreement


(151,965)


(155,000)


(93,000)

Payment of senior notes


-


(200,000)


-

Payment of employee taxes on stock-based compensation


(1,477)


(288)


(2,212)

Payment on seller note and other contingent consideration


(5,197)


(9,128)


(13,561)

Payment of capital lease obligations


(1,210)


(979)


(1,110)

Payment of debt issuance costs and fees


(2,863)


(15,832)


(8,340)

Net cash (used in) provided by financing activities - continuing operations


(33,872)


(103,515)


22,714








(Decrease) increase in cash and cash equivalents


(5,649)


(51,596)


47,054

Cash and cash equivalents, at beginning of year


7,157


58,753


11,699

Cash and cash equivalents, at end of year


$         1,508


$         7,157


$       58,753








 

Table 4

Hanger, Inc.

Segment Information: Revenue, EBITDA and Adjusted EBITDA

(dollars in thousands)








EBITDA is defined as operating income before depreciation and amortization.  Adjusted EBITDA is defined as operating income
before certain charges, impairments of intangible assets, third-party professional fees in excess of normal amounts incurred in
connection with our financial statement remediation, debt extinguishment costs, expenses associated with equity-based
compensation, severance expenses associated with significant reductions in force and expenses incurred in connection with our acquisitions.

We use EBITDA and Adjusted EBITDA as measures to assess the relative level of our indebtedness and our compliance with
certain debt covenants which are based on these measures.   Additionally, we utilize these measures to assess our operating and
financial performance.   We believe that these measures enhance a user's understanding of normal operating income excluding
certain charges, depreciation and amortization. 

Neither EBITDA or Adjusted EBITDA are measures of financial performance computed in accordance with Generally Accepted
Accounting Principles ("GAAP") and should not be considered in isolation nor as a substitute for operating income, net income,
cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a
measure of profitability or liquidity.  In addition, the calculation of EBITDA and Adjusted EBITDA is susceptible to varying
interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other
companies.  EBITDA and Adjusted EBITDA may not be indicative of historical operating results, and we do not intend these
measures to be predictive of future results of operations.










For the Years Ended December 31,



2017


2016


2015








Net Revenue(a)







Patient Care


$     851,973


$     840,130


$     874,960

Products & Services


188,796


201,924


192,212

Net revenue


$  1,040,769


$  1,042,054


$  1,067,172








EBITDA(b)







Patient Care


$     143,781


$     117,622


$   (251,394)

Products & Services


(17,513)


(40,172)


40,655

Corporate & Other


(106,695)


(104,649)


(92,520)

EBITDA (Non-GAAP)


$       19,573


$     (27,199)


$   (303,259)








Adjusted EBITDA(b)







Patient Care


$     148,007


$     122,088


$     134,946

Products & Services


38,504


48,558


45,612

Corporate & Other


(66,908)


(62,187)


(63,401)

Adjusted EBITDA (Non-GAAP)


$     119,603


$     108,459


$     117,157








(a) Excludes intersegment revenue.

(b) EBITDA and Adjusted EBITDA are "Non-GAAP" measures. Please refer to both Table 6 and Table 7 for a reconciliation of these
measures to GAAP net income.

 

Table 5

Hanger, Inc.

Reconciliation of net (loss) and (loss) per share to

adjusted net income and adjusted earnings per share

(dollars in thousands, except share and per share amounts)








Earnings Per Share (or "EPS") is defined as net income divided by our diluted common shares during the applicable period.  
Adjusted EPS is defined as EPS adjusted for impairments of intangible assets, third-party professional fees in excess of normal
amounts incurred in connection with our financial statement remediation, debt extinguishment costs, severance expenses
associated with significant reductions in force and expenses incurred in connection with our acquisitions and certain other charges. 

We utilize Adjusted EPS to assess our operating and financial performance.   We believe that this measure enhances a user's
understanding of normal operating results excluding certain charges. 

Adjusted EPS is not a measure of financial performance computed in accordance with GAAP and should not be considered in
isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or
cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity.  In addition, the calculation of
Adjusted EPS is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to
similarly titled measures of other companies.  Adjusted EPS may not be indicative of historical operating results, and we do not intend
these measures to be predictive of future results of operations.










For the Years Ended December 31,



2017


2016


2015








Net loss - as reported (GAAP)


$   (104,671)


$   (106,471)


$   (327,091)








Adjustments: 







Impairment of intangible assets


54,735


86,164


385,807

Amortization expense


9,527


13,918


13,800

Third party professional fees


32,301


37,244


23,475

Extinguishment of debt


-


6,031


7,237

Severance expenses associated with reduction in force


64


2,487


-

(Income) loss from discontinued operations before taxes


-


(1,425)


11,223

Specified adjustments prior to tax effect


$       96,627


$     144,419


$     441,542








Tax effect of specified adjustments (a)


19,981


(23,974)


(87,436)








Specified adjustments after taxes


116,608


120,445


354,106








Adjusted net income (Non-GAAP) 


$       11,937


$       13,974


$       27,015








Basic and diluted loss per share - as reported (GAAP)


$         (2.89)


$         (2.96)


$         (9.18)

Effect of above listed specified adjustments


3.22


3.35


9.94

Adjusted diluted income per share (Non-GAAP)


$           0.33


$           0.39


$           0.76








Shares used to compute adjusted diluted per common share amounts


36,566,638


36,078,719


35,739,766








(a) "Tax effect of specified adjustments" reflects the difference between the Company's effective provision for taxes and the
application of a combined federal and state statutory tax rate of 38% to the Company's earnings from continuing operations
before taxes, after the incorporation of the identified above adjustments.

 

Table 6

Hanger, Inc.

Reconciliation of net income (loss) to EBITDA and Adjusted EBITDA

(dollars in thousands)








EBITDA is defined as operating income before depreciation and amortization.  Adjusted EBITDA is defined as operating income
before certain charges, impairments of intangible assets, third-party professional fees in excess of normal amounts incurred in
connection with our financial statement remediation, debt extinguishment costs, expenses associated with equity-based
compensation, severance expenses associated with significant reductions in force and expenses incurred in connection with our acquisitions.

We use EBITDA and Adjusted EBITDA as measures to assess the relative level of our indebtedness and our compliance with
certain debt covenants which are based on these measures.   Additionally, we utilize these measures to assess our operating and
financial performance.   We believe that these measures enhance a user's understanding of normal operating income excluding
certain charges, depreciation and amortization. 

Neither EBITDA or Adjusted EBITDA are measures of financial performance computed in accordance with GAAP and should not be
considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of
operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity.  In addition, the
calculation of EBITDA and Adjusted EBITDA is susceptible to varying interpretations and calculations, and the amounts presented
may not be comparable to similarly titled measures of other companies.  EBITDA and Adjusted EBITDA may not be indicative of
historical operating results, and we do not intend these measures to be predictive of future results of operations.










For the Years Ended December 31,



2017


2016


2015








Net loss - as reported (GAAP)


$   (104,671)


$   (106,471)


$   (327,091)








Adjustments to calculate EBITDA: 







Depreciation and amortization


39,259


44,887


46,343

Interest expense, net


57,688


45,199


29,892

Extinguishment of debt


-


6,031


7,237

Provision (benefit) for income taxes


27,297


(15,910)


(67,614)

(Income) loss from discontinued operations, net of income taxes


-


(935)


7,974

Specified adjustments - net loss to EBITDA


124,244


79,272


23,832

EBITDA (Non-GAAP)


19,573


(27,199)


(303,259)








Further adjustments to calculate Adjusted EBITDA:







Impairment of intangible assets


54,735


86,164


385,807

Third-party professional fees


32,301


37,244


23,475

Equity-based compensation


12,930


9,763


11,134

Acquisition-related expenses


-


-


-

Severance expenses associated with reduction in force


64


2,487


-

Specified further adjustments - EBITDA to Adjusted EBITDA


100,030


135,658


420,416

Adjusted EBITDA (Non-GAAP)


$     119,603


$     108,459


$     117,157








 

Table 7

Hanger, Inc.

Segment reconciliation of net income (loss) to EBITDA and Adjusted EBITDA

(dollars in thousands)










For the Years Ended December 31,



2017


2016


2015








Patient Care 














Net income (loss) - as reported (GAAP)


90,350


59,668


(310,745)

Adjustments to calculate EBITDA:







Depreciation and amortization


21,363


24,873


25,674

Interest expense, net


32,068


33,081


33,677

Extinguishment of debt


-


-


-

Provision (benefit) for income taxes


-


-


-

Specified adjustments - net income (loss) to EBITDA


53,431


57,954


59,351

EBITDA (Non-GAAP)


143,781


117,622


(251,394)








Further adjustments to calculate Adjusted EBITDA:







Impairment of intangible assets


-


-


382,860

Third-party professional fees


-


-


-

Equity-based compensation


4,138


2,989


3,480

Acquisition-related expenses


-


-


-

Severance expenses associated with reduction in force


88


1,477


-

Specified further adjustments - EBITDA to Adjusted EBITDA


4,226


4,466


386,340

Adjusted EBITDA (Non-GAAP)


148,007


122,088


134,946








Products & Services 














Net (loss) income - as reported (GAAP)


(40,872)


(64,869)


15,658

Adjustments to calculate EBITDA:







Depreciation and amortization


10,163


11,600


11,883

Interest expense, net


13,196


13,097


13,114

Extinguishment of debt


-


-


-

Provision (benefit) for income taxes


-


-


-

Specified adjustments - net income to EBITDA


23,359


24,697


24,997

EBITDA (Non-GAAP)


(17,513)


(40,172)


40,655








Further adjustments to calculate Adjusted EBITDA:







Impairment of intangible assets


54,735


86,164


2,947

Third-party professional fees


-


-


-

Equity-based compensation


1,306


1,556


2,010

Acquisition-related expenses


-


-


-

Severance expenses associated with reduction in force


(24)


1,010


-

Specified further adjustments - EBITDA to Adjusted EBITDA


56,017


88,730


4,957

Adjusted EBITDA (Non-GAAP)


38,504


48,558


45,612








Corporate & Other














Net loss from continuing operations - as reported (GAAP)


(154,149)


(102,205)


(24,030)

Adjustments to calculate EBITDA:







Depreciation and amortization


7,733


8,414


8,786

Interest expense, net


12,424


(979)


(16,899)

Extinguishment of debt


-


6,031


7,237

Provision (benefit) for income taxes


27,297


(15,910)


(67,614)

Specified adjustments - net loss from continuing operations to EBITDA


47,454


(2,444)


(68,490)

EBITDA (Non-GAAP)


(106,695)


(104,649)


(92,520)








Further adjustments to calculate Adjusted EBITDA:







Impairment of intangible assets


-


-


-

Third-party professional fees


32,301


37,244


23,475

Equity-based compensation


7,486


5,218


5,644

Acquisition-related expenses


-


-


-

Severance expenses associated with reduction in force


-


-


-

Specified further adjustments - EBITDA to Adjusted EBITDA


39,787


42,462


29,119

Adjusted EBITDA (Non-GAAP)


(66,908)


(62,187)


(63,401)

Adjusted EBITDA (Non-GAAP)


$     119,603


$     108,459


$     117,157








 

Table 8

Hanger, Inc.

Indebtedness

(dollars in thousands)






As of December 31,



2017


2016


2015








Term loan due June, 2018


$     151,875


$     180,000


$     199,688

Term loan B, due August, 2019


280,000


280,000


-

Revolving credit facility


5,000


-


132,000

Senior notes due 2018


-


-


200,000

Seller notes


5,912


11,110


19,838

Financing leases and other


18,169


18,245


21,134

Total debt before unamortized discount and debt issuance costs


460,956


489,355


572,660








Unamortized discount


(5,556)


(7,511)


(1,820)

Debt issuance costs, net


(5,136)


(9,194)


(4,407)

Total debt


$     450,264


$     472,650


$     566,433








Reported as:







Current portion of long-term debt


$         4,336


$       30,944


$       30,385

Long-term debt


445,928


441,706


536,048

Total debt


$     450,264


$     472,650


$     566,433








 

Table 9

Hanger, Inc.

Key Operating Metrics










As of and for the Years Ended December 31,



2017


2016


2015








Same clinic revenue growth per day (a): 







Growth rate on net revenue


2.2%


(2.4)%


5.7%

Growth rate excluding favorable effect of change in rate of
disallowances


0.8%


(3.1)%


3.1%








Clinical locations:







Patient care clinics


682


706


721

Satellite clinics


112


115


116

Total clinical locations


794


821


837















(a) Same Clinic Revenue per Day - Same Clinic Revenue per Day normalizes sales for the number of days a clinic was open in
each comparable period. These measures are both non-GAAP and unaudited.

 

 

Cision View original content:http://www.prnewswire.com/news-releases/hanger-reports-full-year-2017-results-300648016.html

SOURCE Hanger, Inc.

Nachrichten zu Hanger Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Hanger Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!